Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2022 Results Conference Call August 8, 2022 4:30 PM ET
Company Participants
Iris Francesconi - Head of Investor Relations
Christopher Posner - President and Chief Executive Officer
Richard Makara - Interim Chief Financial Officer
Joana Goncalves - Chief Medical Officer
Conference Call Participants
Daniel Wolle - JPMorgan
Christopher Howerton - Jefferies
Joseph Stringer - Needham & Company
David Amsellem - Piper Sandler
Oren Livnat - H.C. Wainwright
Jason Gerberry - Bank of America
Operator
Good afternoon. My name is Denise, and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics’ Second Quarter 2022 Financial Results and Update Conference Call. All lines have been placed on-mute to avoid any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that this call is being recorded.
At this time, I would now like to introduce Iris Francesconi, Chief Strategy Officer and Head of Investor Relations from Cara Therapeutics. Ms. Francesconi, you may begin your call.
Iris Francesconi
Thank you, Denise, and good afternoon. Just after market closed today, we issued a press release detailing our corporate progress and financial results for the second quarter 2022. The press release can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call on the Investors section of the website.
Participating in today's call are Chris Posner, Cara's President and Chief Executive Officer; Rick Makara, Cara's Interim Chief Financial Officer; and Dr. Joana Goncalves, Cara's Chief Medical Officer.
Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are Forward-Looking Statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these Forward-Looking Statements include statements concerning the Company’s ability to successfully commercialize KORSUVA injection and Kapruvia, risks that KORSUVA injection and Kapruvia revenue, expenses and cost may not be as expected. Planned future regulatory meetings and/or submissions and potential future regulatory approvals; the performance of the Company' commercial partners including Vifor; expected timing of the initiation, enrollment and data readouts from the Company’s planned and ongoing clinical trials; the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the Company’s products candidates; the potential for the Company’s products candidates to be alternatives in therapeutic areas investigated including NP; and the potential for Oral difelikefalin to address additional pruritic indications, the size and growth of the potential markets for pruritus, the Company’s expected cash reach, and the potential impact of COVID-19, geopolitical tensions and macroeconomic conditions on the Company’s clinical development and regulatory timelines and plans.